Managed Care Forum: Emerging Therapies in Metastatic Colorectal Cancer Join us online for this informative symposium on managed care implications of emerging therapies in metastatic colorectal cancer (MCRC).

Click To View Webcast (requires free RealPlayer® plug-in)

Dear Colleague:

Recent advances in biotechnology have led to the development of sophisticated and targeted therapies that could dramatically change the care of patients with colorectal cancer in the coming years. Colorectal cancer is the third most common malignancy in both genders in the United States, and the majority of patients either present with or progress to metastases. The best chemotherapy regimens available today only marginally improve survival, so there is great room for therapeutic advance in this field, and emerging therapies are eagerly being watched. 

The emergence of whole classes of new drugs raises important issues not only for patients and healthcare providers but for the managed care industry as well. How and for whom will these new therapies be used? Will they be used alone or with existing therapies? What clinical benefits will they offer? How much will they cost and will they reduce other healthcare costs as a result of their improved efficacy? What related case management services should be provided to targeted patient populations to help improve clinical outcomes and reduce overall costs? 

Join us on the Internet for a live Webcast in which expert faculty in medicine, managed care pharmacy, and nursing case management explore these issues. Emerging Therapies in Metastatic Colorectal Cancer: The Latest Evidence will address some of your most important concerns regarding the changing management of colorectal cancer. It is sure to be an informative and valuable conference. 

Sincerely,

Joel Picus, MD

Chair

CHAIR

Joel Picus, MD
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

FACULTY

Steven G. Avey, MS, RPh
Executive Director
Foundation for Managed Care Pharmacy
Alexandria, Virginia

Howard I. Cohen, RPh, MS, FASHP
Director of Pharmacy Services
Thomas Jefferson University Hospitals, Inc
Philadelphia, Pennsylvania

Robert B. Diasio, MD
Professor of Medicine and Pharmacology
Department of Pharmacology & Toxicology
The University of Alabama at Birmingham
Birmingham, AL

Axel Grothey, MD
Mayo Foundation Scholar
Department of Medical Oncology
Mayo Clinic College of Medicine
Rochester, MN

Frances B. Martini, RN, BSN, MBA
Vice President, Care Management
Health Net of the Northeast, Inc
Shelton, Connecticut


top

Target Audience

This activity has been designed for medical directors, pharmacy directors, and nurse case managers who care for patients with MCRC.

Activity Goal

The goal of this professional education activity is to review treatment options for patients with MCRC.

top

Learning Objectives

After completing this course, the participant should be able to:

• Discuss the safety and efficacy of currently available treatments for MCRC.
  
• Review current data on the safety and efficacy of new targeted therapies, including angiogenesis inhibitors, in the treatment of MCRC.
  
• Develop appropriate strategies for managing side effects of current MCRC therapies.
• Consider the impacts of therapies for MCRC on the patient, the caregiving facility, and the payer, including clinical benefit and pharmacoeconomic considerations.
  
• Evaluate emerging therapies for inclusion in formulary.
  
• Identify and address needs of individual patients to provide best of care services and optimal patient outcome.
  

top

AGENDA

Current and Emerging Therapies in MCRC
Joel Picus, MD - 15 minutes

Symptom Management of Therapies for MCRC
Howard I. Cohen, RPh, MS, FASHP - 10 minutes

Evidence-Based Approach to Evaluating Drugs for MCRC
Steven G. Avey, MS, RPh - 10 minutes

Optimizing Case Management for MCRC Patients
Frances B. Martini, RN, BSN, MBA - 10 minutes

Live, Interactive Discussion with Faculty
- 15 minutes

top

CME/CE Information

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Information for Pharmacists

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to this program, for 1 contact hour (0.1 CEU), is 052-000-04-001-L04.

CE Information for Nurses

The National Center for Advanced Medical Education (a division of CMEinfo.com) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The National Center for Advanced Medical Education (a division of CMEinfo.com) designates this educational activity for 1.2 contact hours. Provider approved by the California Board of Registered Nursing, Provider Number 13776 for 1.2 contact hours.

CE Information for Certified Case Managers

This program has been approved for 1 clock hour by the Commission for Case Manager Certification. Approval number: 7580117578.

There is no charge for this activity.


top

Disclosure Information

The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Faculty Disclosure

Steven G. Avey, MS, RPh, has indicated no significant relationships.

Howard I. Cohen, RPh, MS, FASHP, is on the Hope speakers bureau.

Axel Grothey, MD, has received grant/research support from Roche Pharmaceuticals and Sanofi-Synthelabo; is on the speakers bureau of Genentech, Inc, Roche Pharmaceuticals, and Sanofi-Synthelabo; is a consultant for Sanofi-Synthelabo; and has received honoraria from Pfizer Inc, Roche Pharmaceuticals, and Sanofi-Synthelabo.

Robert B. Diasio, MD, has received grant/research support from Pfizer Inc, Roche Pharmaceuticals, Sanofi-Synthelabo, Inc; is on the speaker's bureau of, is a consultant for and has received honoraria from Bristol-Myers Squibb Company, Genentech Inc, Pfizer Inc, Roche Pharmaceuticals, and Sanofi-Synthelabo; and is a consultant for Taiho Pharmaceutical.

Frances B. Martini, RN, BSN, MBA, has indicated no significant relationships.

Joel Picus, MD, is on the speakers bureau of and is a consultant for Genentech, Inc; he is also on the speakers bureau of Pharmacia & Upjohn.

There will be no discussion of unlabeled/unapproved uses of drugs or devices in this activity.

The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge, or The National Center for Advanced Medical Education (a division of CMEinfo.com).

This CME/CE activity is provided by Projects In Knowledge, and the nursing CE activity is provided by The National Center for Advanced Medical Education (a division of CMEinfo.com), solely as an educational service. Please note that although faculty will discuss specific treatment modalities, neither Projects In Knowledge, the accredited and approved CME/CE provider, nor The National Center for Advanced Medical Education (a division of CMEinfo.com), the accredited and approved nursing CE provider, nor their CME/CE regulatory bodies, including the ANCC, endorse any of the modalities mentioned in the course of discussion. Specific patient care decisions are the responsibility of the healthcare professional caring for the patient.

This independent CME/CE activity is supported by an educational grant from Genentech, Inc.

top

Recommend this to a colleague